Stifel resumed coverage of Fulcrum Therapeutics (FULC) with a Buy rating and $20 price target Recent 12mg data already support a “compelling profile” for pociredir and the “bar” for the full 20mg cohort is low, argues the analyst, who adds that there’s “a blockbuster opportunity that supports meaningful upside” even as Fulcrum’s trial population and criteria exists today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics’ Earnings Call Highlights Progress and Potential
- Fulcrum Therapeutics price target raised to $16 from $12.50 at Piper Sandler
- Fulcrum Therapeutics Reports Q3 2025 Progress and Financials
- Fulcrum Therapeutics reports Q3 EPS (31c), consensus (29c)
- Promising Preclinical Data and Strategic Expansion Drive Buy Rating for Fulcrum Therapeutics